Skip to content
Rheumatology Letter
  • Blog
  • About Us
  • Annals of Rheumatic Diseases
  • Current Opinion in Rheumatology
  • European Review | Rheumatology
  • Google News
  • Helio.com
  • JCR
  • Medpage
  • Medscape
  • Nature Reviews Rheumatology
  • NEJM
  • News-Medical.net | Rheumatology
  • Newsletters
  • PubMed
  • Rheumatology
  • Rheumatology Network Articles
  • RheumNow
  • Scandinavian Journal of Rheumatology
  • Science Direct
  • The Journal of Rheumatology
  • The Lancet
  • The Rheumatologist
  • Wiley
  • Blog
  • About Us
  • Annals of Rheumatic Diseases
  • Current Opinion in Rheumatology
  • European Review | Rheumatology
  • Google News
  • Helio.com
  • JCR
  • Medpage
  • Medscape
  • Nature Reviews Rheumatology
  • NEJM
  • News-Medical.net | Rheumatology
  • Newsletters
  • PubMed
  • Rheumatology
  • Rheumatology Network Articles
  • RheumNow
  • Scandinavian Journal of Rheumatology
  • Science Direct
  • The Journal of Rheumatology
  • The Lancet
  • The Rheumatologist
  • Wiley
logo
RheumNow

Telitacicept Effective in Systemic Lupus Erythematosus The NEJM has published a report from van Vollenhoven et al show

  • by admin
  • October 20, 2025
Telitacicept Effective in Systemic Lupus Erythematosus The NEJM has published a report from van Vollenhoven et al… Read More
PubMed

Association between the CRP-TyG index and lupus nephritis risk

  • by admin
  • October 20, 2025
Biomol Biomed. 2025 Oct 20. doi: 10.17305/bb.2025.13043. Online ahead of print. ABSTRACT Assessment of insulin resistance is… Read More
RheumNow

SAIL-RA: Finding ILD in Early RA Cohort study of early rheumatoid arthritis (RA) patients finds that interstitial lung

  • by admin
  • October 20, 2025
SAIL-RA: Finding ILD in Early RA Cohort study of early rheumatoid arthritis (RA) patients finds that interstitial… Read More
RheumNow

FDA Approves Obinutuzumab for Active Lupus Nephritis

  • by admin
  • October 20, 2025
FDA Approves Obinutuzumab for Active Lupus Nephritis jjcush@gmail.com Mon, 10/20/2025 – 18:17 Read More
RheumNow

FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lu

  • by admin
  • October 20, 2025
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lu https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg… Read More
Medpage

Who Knew? Autoimmunity Might Actually Benefit Some Cancer Patients

  • by admin
  • October 20, 2025
(MedPage Today) — Chimeric antigen receptor (CAR) T-cell therapy for blood cancers appeared less toxic, and patients’… Read More
Google News

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function …

  • by admin
  • October 20, 2025
Poster to be presented at American College of Rheumatology Convergence 2025 –BRISBANE, Calif., Oct. 20, 2025 (GLOBE… Read More
RheumNow

Retrospective study of 423 seropositiv RA pts (SPRA) finds 21% with baseline ILD; over 10 yrs 31% had ILD. High monocyte

  • by admin
  • October 20, 2025
Retrospective study of 423 seropositiv RA pts (SPRA) finds 21% with baseline ILD; over 10 yrs 31%… Read More
Google News

A Case of Isolated Extramedullary Plasmacytoma of the Sternoclavicular joint – PubMed

  • by admin
  • October 20, 2025
Department of Rheumatology, Shaoxing Shangyu District Hospital of Traditional Chinese Medicine, Shaoxing, Zhejiang Province, 312300, People’s Republic … Read More
Google News

FDA approves Gazyva for lupus nephritis, marking ‘significant advancement’ for patients

  • by admin
  • October 20, 2025
For more information: Shivani Garg, MD, PhD, can be reached at sgarg@medicine.wisc.edu. Published by: healio rheumatology logo.… Read More
1 2 3 … 396

NewsBe Made by Couponvario | Powered by WordPress